Clover Biopharmaceuticals and Adimmune have signed an exclusive agreement to commercialise the latter’s AdimFlu-S (QIS) influenza vaccine in mainland China.

Under the deal, Clover will also have exclusive rights to commercialise the influenza vaccine in Brazil, Bangladesh, and the Philippines, upon receipt of regulatory approvals.

The company will also get an opportunity to collaborate with Adimmune to develop additional vaccine candidates, including next-generation vaccines for influenza.

The quadrivalent split-inactivated vaccine AdimFlu-S (QIS) has been developed to prevent influenza.

It comprises hemagglutinin from four strains of influenza virus (two A and two B), so the vaccine has the potential to show high effectiveness against seasonal influenza vaccine relative to trivalent options.

In January last year, the China National Medical Products Administration (NMPA) approved the vaccine for individuals aged three years and above.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

AdimFlu-S (QIS) is claimed to be the only imported quadrivalent seasonal influenza vaccine approved in the country.

It is expected to be launched in the second half of this year.

Clover CEO and executive director Joshua Liang said: “We are delighted to form this strategic partnership with Adimmune, a company with a stellar track record in manufacturing and supplying critical vaccines to populations in Asia, particularly as the market for flu vaccines generally, and quadrivalent vaccines specifically, is poised for significant growth in mainland China.

“This partnership also brings Clover one step closer to establishing a leading respiratory vaccine franchise and allows us to realise synergies with the ongoing commercialisation of our Covid-19 vaccine.”

Adimmune will manufacture the vaccine at its facility that has been certified by the US Food and Drug Administration (FDA), the European Medicines Agency (EMA), and many other agencies for good manufacturing practices (GMP).